AGNPF
Price
$0.05
Change
-$0.01 (-16.67%)
Updated
Jul 2 closing price
Capitalization
1.3M
PHIO
Price
$2.40
Change
-$0.08 (-3.23%)
Updated
Jul 3 closing price
Capitalization
11.52M
Interact to see
Advertisement

AGNPF vs PHIO

Header iconAGNPF vs PHIO Comparison
Open Charts AGNPF vs PHIOBanner chart's image
Algernon Pharmaceuticals
Price$0.05
Change-$0.01 (-16.67%)
Volume$66.71K
Capitalization1.3M
Phio Pharmaceuticals
Price$2.40
Change-$0.08 (-3.23%)
Volume$84.05K
Capitalization11.52M
AGNPF vs PHIO Comparison Chart in %
Loading...
AGNPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PHIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AGNPF vs. PHIO commentary
Jul 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AGNPF is a Hold and PHIO is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 06, 2025
Stock price -- (AGNPF: $0.05 vs. PHIO: $2.40)
Brand notoriety: AGNPF and PHIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AGNPF: 247% vs. PHIO: 12%
Market capitalization -- AGNPF: $1.3M vs. PHIO: $11.52M
AGNPF [@Biotechnology] is valued at $1.3M. PHIO’s [@Biotechnology] market capitalization is $11.52M. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AGNPF’s FA Score shows that 2 FA rating(s) are green whilePHIO’s FA Score has 0 green FA rating(s).

  • AGNPF’s FA Score: 2 green, 3 red.
  • PHIO’s FA Score: 0 green, 5 red.
According to our system of comparison, AGNPF is a better buy in the long-term than PHIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AGNPF’s TA Score shows that 1 TA indicator(s) are bullish while PHIO’s TA Score has 3 bullish TA indicator(s).

  • AGNPF’s TA Score: 1 bullish, 5 bearish.
  • PHIO’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, PHIO is a better buy in the short-term than AGNPF.

Price Growth

AGNPF (@Biotechnology) experienced а -14.85% price change this week, while PHIO (@Biotechnology) price change was +8.60% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

PHIO is expected to report earnings on May 15, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PHIO($11.5M) has a higher market cap than AGNPF($1.3M). AGNPF has higher P/E ratio than PHIO: AGNPF (2.21) vs PHIO (0.01). PHIO YTD gains are higher at: 33.333 vs. AGNPF (4.827). AGNPF has higher annual earnings (EBITDA): -1.62M vs. PHIO (-7.05M). PHIO has more cash in the bank: 13.3M vs. AGNPF (92.2K). AGNPF (0) and PHIO (0) have equivalent revenues.
AGNPFPHIOAGNPF / PHIO
Capitalization1.3M11.5M11%
EBITDA-1.62M-7.05M23%
Gain YTD4.82733.33314%
P/E Ratio2.210.0118,142%
Revenue00-
Total Cash92.2K13.3M1%
Total DebtN/A0-
FUNDAMENTALS RATINGS
AGNPF vs PHIO: Fundamental Ratings
AGNPF
PHIO
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
58
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
3398
PRICE GROWTH RATING
1..100
8438
P/E GROWTH RATING
1..100
8069
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AGNPF's Valuation (27) in the null industry is in the same range as PHIO (58) in the Biotechnology industry. This means that AGNPF’s stock grew similarly to PHIO’s over the last 12 months.

AGNPF's Profit vs Risk Rating (100) in the null industry is in the same range as PHIO (100) in the Biotechnology industry. This means that AGNPF’s stock grew similarly to PHIO’s over the last 12 months.

AGNPF's SMR Rating (33) in the null industry is somewhat better than the same rating for PHIO (98) in the Biotechnology industry. This means that AGNPF’s stock grew somewhat faster than PHIO’s over the last 12 months.

PHIO's Price Growth Rating (38) in the Biotechnology industry is somewhat better than the same rating for AGNPF (84) in the null industry. This means that PHIO’s stock grew somewhat faster than AGNPF’s over the last 12 months.

PHIO's P/E Growth Rating (69) in the Biotechnology industry is in the same range as AGNPF (80) in the null industry. This means that PHIO’s stock grew similarly to AGNPF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AGNPFPHIO
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
74%
Bearish Trend 3 days ago
89%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
79%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
82%
Advances
ODDS (%)
N/A
Bullish Trend 5 days ago
82%
Declines
ODDS (%)
N/A
Bearish Trend 13 days ago
90%
BollingerBands
ODDS (%)
N/A
Bearish Trend 3 days ago
88%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
76%
View a ticker or compare two or three
Interact to see
Advertisement
AGNPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PHIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AEI1.060.03
+2.91%
Alset
LPLA384.117.64
+2.03%
LPL Financial Holdings
UNFI23.260.22
+0.95%
United Natural Foods
QFIN42.74N/A
N/A
Qifu Technology
FINW15.67-0.05
-0.32%
FinWise Bancorp

AGNPF and

Correlation & Price change

A.I.dvisor tells us that AGNPF and CYDY have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AGNPF and CYDY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AGNPF
1D Price
Change %
AGNPF100%
N/A
CYDY - AGNPF
24%
Poorly correlated
+5.56%
WVE - AGNPF
23%
Poorly correlated
+2.96%
PHIO - AGNPF
21%
Poorly correlated
-3.23%
IBIO - AGNPF
20%
Poorly correlated
+0.14%
ABCZF - AGNPF
12%
Poorly correlated
N/A
More